Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RYTM, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
RYTM reported $330.9M in cash and short-term investments (as of Jun 30, 2026) and used about $26.9M/quarter in operations, an estimated runway of 36.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RYTM files for a raise →
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-03-20 | IMCIVREE | sNDA | -10.9% | -3.2% | -9.3% |
| 2025-12-20 | — | sNDA | +8.7% | +0.7% | +0.4% |
| 2025-11-07 | — | sNDA | -1.7% | +1.8% | -2.6% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RYTM and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →